Thermedical has received US Food and Drug Administration (FDA) approval for a clinical trial of its Saline Enhanced Radiofrequency (SERF) Ablation System.
The single-arm, open-label interventional clinical study has been designed to assess the efficacy and safety of the SERF Ablation System with Durablate Catheter in ventricular tachycardia (VT) patients who are resistant to antiarrhythmic drugs or standard ablation procedures.
